Sonnet BioTherapeutics (SONN)

Company Profile

Founded in 2011, Sonnet Biotherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and 'hitch-hikes' on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Company profile

Ticker

SONN

Exchange

NASDAQ

Website

sonnetbio.com

CEO

Michael Pruitt

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Sep 30

Sector

Accommodation and Food Services > Food Service Contractors

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Abbott Laboratories • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

Chanticleer Holdings, Inc., TULVINE SYSTEMS INC

SEC CIK

0001106838

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Sonnet BioTherapeutics, Inc. • Sonnet BioTherapeutics CH SA • SonnetBio Pty Ltd ...

IRS number

522102141

SONN stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

10 May 23

Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update

10 May 23

8-K

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

18 Apr 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

24 Mar 23

8-K

Regulation FD Disclosure

Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update

13 Feb 23

8-K

Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering

13 Feb 23

424B4

Prospectus supplement with pricing info

9 Feb 23

EFFECT

Notice of effectiveness

8 Feb 23

Latest ownership filings

View all

Financial summary

Financial statements Chart SONN financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 22	Sep 21	Sep 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q1 2023

SONN institutional ownership history Ownership history

26.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	18	14	+28.6%
Opened positions	9	4	+125.0%
Closed positions	5	3	+66.7%
Increased positions	2	6	-66.7%
Reduced positions	2	3	-33.3%

13F shares	Current	Prev Q	Change
Total value	2.62 bn	71.95 mm	+3546.0%
Total shares	7.31 mm	373.75 k	+1855.2%
Total puts	0.00	0.00
Total calls	848.00 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Anson Funds Management	1.76 mm	$633.60 mm	NEW
Walleye Capital	1.66 mm	$599.25 mm	NEW
Sabby Management	1.22 mm	$437.59 mm	NEW
Alyeska Investment	951.81 k	$342.65 mm	NEW
Ayrton Capital	765.43 k	$275.55 mm	NEW
CVI	701.63 k	$252.59 mm	NEW
Boothbay Fund Management	136.23 k	$49.04 mm	NEW
Geode Capital Management	28.92 k	$10.41 mm	-1.9%
Vanguard	18.06 k	$6.50 mm	0.0%
NTRS Northern Trust	17.85 k	$6.43 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Anson Funds Management	1.76 mm	+1.76 mm	NEW
Walleye Capital	1.66 mm	+1.66 mm	NEW
Sabby Management	1.22 mm	+1.22 mm	NEW
Alyeska Investment	951.81 k	+951.81 k	NEW
Ayrton Capital	765.43 k	+765.43 k	NEW
CVI	701.63 k	+701.63 k	NEW
Hudson Bay Capital Management	0.00	-242.86 k	EXIT
Boothbay Fund Management	136.23 k	+136.23 k	NEW
Two Sigma Securities	0.00	-18.00 k	EXIT
NTRS Northern Trust	17.85 k	+17.85 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SONN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 May 23	Dyrness Albert D.	Common Stock	Buy	Acquire P	No	No	0.468	23,255	10.88 k	28,962
17 May 23	Nailesh Bhatt	Common Stock	Buy	Acquire P	No	No	0.232	25,000	5.80 k	30,733
15 May 23	Mohan Pankaj	Common Stock	Buy	Acquire P	No	No	0.223	371,600	82.87 k	553,331
15 Mar 23	Mohan Pankaj	Common Stock	Buy	Acquire P	No	No	0.585	60,000	35.10 k	181,731
6 Feb 23	John Harry Cross III	Common Stock	Payment of exercise	Dispose F	No	No	1.06	1,960	2.08 k	23,927